ArticleThe British journal of dermatology2014
Propranolol targets the contractility of infantile haemangioma-derived pericytes.
Article in The British journal of dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 58 citations in OpenAlex.
- Multi-omics unravels multiple pharmacological actions in a murine model of infantile hemangioma receiving oxymatrine therapy.Discover oncology · 2026Article
- R-(+)-propranolol for infantile hemangioma:Frontiers in medicine · 2026Review
- Propranolol (1 mg/kg/day) with intralesional bleomycin versus propranolol monotherapy for infantile hemangioma: a randomized controlled trial.Frontiers in pharmacology · 2025Article
- Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.Frontiers in oncology · 2025Review
- Recent advances in the role of neuroregulation in skin wound healing.Burns & trauma · 2025Review
- Infantile hemangioma: the common and enigmatic vascular tumor.The Journal of clinical investigation · 2024Review
- Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Evaluation of Transdermal Transport and Concurrent Cutaneous Hydrolysis of Timolol Prodrug for the Treatment of Infantile Hemangiomas.Pharmaceutics · 2022Article
- A transcription factor is the target of propranolol treatment in infantile hemangioma.The Journal of clinical investigation · 2022Article
- Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.The Journal of clinical investigation · 2022Article
- A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy.BioMed research international · 2022Article
- Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma.Frontiers in pediatrics · 2022Article
- Case report: Deterioration of infantile hemangioma related to oral or nebulized administration of β2-AR agonist: Three cases reports.Frontiers in oncology · 2022Article
- Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis.Molecular and clinical oncology · 2021Article
- Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.BioMed research international · 2021Article
- Article
- Short-term curative effect and safety of propranolol combined with laser in the treatment of infantile hemangiomas.Oncology letters · 2018Article
- Analysis of Follicle-Stimulating Hormone Receptor in Infantile Hemangioma.Annals of plastic surgery · 2018Article
- Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPropranolol, a β-adrenergic receptor (AR) antagonist, is an effective treatment for endangering infantile haemangioma (IH). Dramatic fading of cutaneous colour is often seen a short time after initiating propranolol therapy, with accelerated regression of IH blood vessels discerned after weeks to months.
objectivesTo assess a possible role for haemangioma-derived pericytes (HemPericytes) isolated from proliferating and involuting phase tumours in apparent propranolol-induced vasoconstriction.
methodsHemPericytes were assayed for contractility on a deformable silicone substrate: propranolol (10 μmol L(-1)) restored basal contractile levels in HemPericytes that were relaxed with the AR agonist epinephrine. Small interfering RNA knockdown of β2-AR blunted this response. HemPericytes and haemangioma-derived endothelial cells were co-implanted subcutaneously in nude mice to form blood vessels; at day 7 after injection, mice were randomized into vehicle and propranolol-treated groups.
resultsHemPericytes expressed high levels of β2-AR mRNA compared with positive control bladder smooth muscle cells. In addition, β2-AR mRNA levels were relatively high in IH specimens (n = 15) compared with β1-AR, β3-AR and α1b-AR. Normal human retinal and placental pericytes were not affected by epinephrine or propranolol in this assay. Propranolol (10 μmol L(-1)) inhibited the proliferation of HemPericytes in vitro, as well as normal pericytes, indicating a nonselective effect in this assay. Contrast-enhanced microultrasonography of the implants after 7 days of treatment showed significantly decreased vascular volume in propranolol-treated animals, but no reduction in vehicle-treated animals.
conclusionsThese findings suggest that the mechanism of propranolol's effect on proliferating IH involves increased pericytic contractility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.